{
  "cap_table": {
    "company": "Thermo Fisher Scientific Inc.",
    "cash_and_equivalents": 4576,
    "debt": [
      {
        "type": "Revolving Credit Facility",
        "amount": 0,
        "ppc_holdings": "-",
        "coupon": "S + 80-150",
        "secured": "N",
        "maturity": "2027"
      },
      {
        "type": "Senior Notes",
        "amount": 35303,
        "ppc_holdings": "-",
        "coupon": null,
        "secured": "N",
        "maturity": null
      },
      {
        "type": "(Less: Debt Issuance Costs)",
        "amount": 172,
        "ppc_holdings": "-",
        "coupon": "-",
        "secured": "-",
        "maturity": "-"
      }
    ],
    "total_debt": 35033,
    "book_value_of_equity": 50512,
    "book_capitalization": 85545,
    "market_value_of_equity": null,
    "market_capitalization": null,
    "ltm_adj_ebitda": null,
    "key_financial_ratios": {
      "total_debt_to_adj_ebitda": "-",
      "total_debt_to_market_capitalization": "-"
    }
  },
  "source_lineage": {
    "ticker": "TMO",
    "metrics": {
      "cash_and_equivalents": {
        "final_value": 4576,
        "unit": "USD_thousands",
        "calculation": "cash_and_cash_equivalents",
        "components": {
          "cash_and_cash_equivalents": 4576
        },
        "sources": {
          "cash_and_cash_equivalents": {
            "type": "table",
            "value": 4576,
            "filing_type": "10-Q",
            "period": "Q2 2025",
            "table": "Condensed Consolidated Balance Sheets",
            "location": {
              "page": 3,
              "row": "Cash and cash equivalents",
              "column": "June 28, 2025",
              "section": "Assets"
            }
          }
        }
      },
      "revolving_credit_facility_amount": {
        "final_value": 0,
        "unit": "USD_thousands",
        "calculation": null,
        "components": {},
        "sources": {
          "revolving_credit_facility_amount": {
            "type": "text",
            "value": 0,
            "filing_type": "10-Q",
            "period": "Q2 2025",
            "location": {
              "page": 12,
              "section": "Note 3. Debt and Other Financing Arrangements"
            },
            "text_snippet": "As of June 28, 2025, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit."
          }
        }
      },
      "revolving_credit_facility_coupon": {
        "final_value": "S + 80-150",
        "unit": null,
        "calculation": null,
        "components": {},
        "sources": {
          "revolving_credit_facility_coupon": {
            "type": "text",
            "value": "S + 80-150",
            "filing_type": "10-K",
            "period": "2024",
            "location": {
              "page": 48,
              "section": "Note 3. Debt and Other Financing Arrangements"
            },
            "text_snippet": "The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), a Euro Interbank Offered Rate (EURIBOR)-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company\u2019s option. ... The margin ranges from 0.70% to 1.40%."
          }
        }
      },
      "revolving_credit_facility_secured": {
        "final_value": "N",
        "unit": null,
        "calculation": null,
        "components": {},
        "sources": {
          "revolving_credit_facility_secured": {
            "type": "text",
            "value": "N",
            "filing_type": "10-K",
            "period": "2024",
            "location": {
              "page": 48,
              "section": "Note 3. Debt and Other Financing Arrangements"
            },
            "text_snippet": "The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit."
          }
        }
      },
      "revolving_credit_facility_maturity": {
        "final_value": "2027",
        "unit": null,
        "calculation": null,
        "components": {},
        "sources": {
          "revolving_credit_facility_maturity": {
            "type": "text",
            "value": "2027",
            "filing_type": "10-Q",
            "period": "Q2 2025",
            "location": {
              "page": 12,
              "section": "Note 3. Debt and Other Financing Arrangements"
            },
            "text_snippet": "The Facility expires on January 7, 2027."
          }
        }
      },
      "senior_notes_amount": {
        "final_value": 35303,
        "unit": "USD_thousands",
        "calculation": null,
        "components": {},
        "sources": {
          "senior_notes_amount": {
            "type": "table",
            "value": 35303,
            "filing_type": "10-Q",
            "period": "Q2 2025",
            "table": "Note 3. Debt and Other Financing Arrangements",
            "location": {
              "page": 11,
              "row": "Total borrowings at par value",
              "column": "June 28, 2025",
              "section": "Debt and Other Financing Arrangements"
            }
          }
        }
      },
      "less_debt_issuance_costs": {
        "final_value": 172,
        "unit": "USD_thousands",
        "calculation": null,
        "components": {},
        "sources": {
          "less_debt_issuance_costs": {
            "type": "table",
            "value": 172,
            "filing_type": "10-Q",
            "period": "Q2 2025",
            "table": "Note 3. Debt and Other Financing Arrangements",
            "location": {
              "page": 11,
              "row": "Unamortized debt issuance costs",
              "column": "June 28, 2025",
              "section": "Debt and Other Financing Arrangements"
            }
          }
        }
      },
      "total_debt": {
        "final_value": 35033,
        "unit": "USD_thousands",
        "calculation": "senior_notes_amount - less_debt_issuance_costs",
        "components": {
          "senior_notes_amount": 35303,
          "less_debt_issuance_costs": 172
        },
        "sources": {
          "senior_notes_amount": {
            "ref_metric": "senior_notes_amount"
          },
          "less_debt_issuance_costs": {
            "ref_metric": "less_debt_issuance_costs"
          }
        }
      },
      "book_value_of_equity": {
        "final_value": 50512,
        "unit": "USD_thousands",
        "calculation": "total_thermo_fisher_scientific_inc_shareholders_equity",
        "components": {
          "total_thermo_fisher_scientific_inc_shareholders_equity": 50512
        },
        "sources": {
          "total_thermo_fisher_scientific_inc_shareholders_equity": {
            "type": "table",
            "value": 50512,
            "filing_type": "10-Q",
            "period": "Q2 2025",
            "table": "Condensed Consolidated Balance Sheets",
            "location": {
              "page": 3,
              "row": "Total Thermo Fisher Scientific Inc. shareholders\u2019 equity",
              "column": "June 28, 2025",
              "section": "Equity"
            }
          }
        }
      },
      "book_capitalization": {
        "final_value": 85545,
        "unit": "USD_thousands",
        "calculation": "total_debt + book_value_of_equity",
        "components": {
          "total_debt": 35033,
          "book_value_of_equity": 50512
        },
        "sources": {
          "total_debt": {
            "ref_metric": "total_debt"
          },
          "book_value_of_equity": {
            "ref_metric": "book_value_of_equity"
          }
        }
      }
    }
  }
}